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We describe a patient with a 35-year history of a severe chronic pelvic pain syndrome (CPPS) that failed to adequately respond to
various drug therapies and other treatments by different specialists. In addition to the ongoing chronic pain, he suffered fromweek-
long episodes of increased pain with no discernible trigger. At the first consultation with us the patient was in a particularly severe
pain phase. He was taking four different analgesically effective drugs. In terms of therapeutic local anesthesia (neural therapy),
we performed suprapubic injection of procaine 1% with infiltration of the vesicoprostatic plexus. Just a few minutes later, the
pain decreased significantly. To maintain and further increase the effect, we performed the injection six more times. The patient
gradually reduced and stopped all drugs and remained free of pain and discomfort ever since. This is the first report of a successful
therapeutic infiltration of the vesicoprostatic plexus using a local anesthetic (LA) in a patient with CPPS that has been refractory
to different treatments for many years. A possible explanation may be that the positive feedback loops maintaining pain and
neurogenic inflammation are disrupted by LA infiltration. This can lead to a new organisation (self-organisation) of the pain-
processing systems.
1. Introduction
Chronic pelvic pain syndrome (CPPS)—also called chronic
(abacterial) prostatitis (CP) in men—is a common clinical
syndrome characterized by pain and functional urogenital
disorders. The National Institute of Health (NIH) assigns
CPPS to Category III prostatitis ((I) acute bacterial prostati-
tis, (II) chronic bacterial prostatitis, (III) chronic prostati-
tis/CPPS, and (IV) asymptomatic inflammatory prostatitis).
Epidemiology. The prevalence of CP/CPPS is 2–10% and
highest in the fifth decade of life [1, 2].
Symptomatology. Typically, pain occurs deeply in the abdo-
men, the perineum, penis, and testes. It may cause symptoms
such as dysuria, sensation of residual urine, permanent
urgency, pollakisuria, nocturia, bladder obstruction with
emptying disorders, and pathological stool urgency or foreign
body sensation in the anus.
Etiology. The etiology of CPPS is unknown. There is no cor-
relation of disorders with histological signs of inflammation
of the prostate [1, 3].
Diagnosis and Differential Diagnosis. CPPS is an exclusion
diagnosis without any internationally standardized diagnos-
tic procedure. To be excluded there are, among others, chron-
ic bacterial prostatitis, urethritis, urogenital malignancy,
stricture, neurological disorders with impaired bladder func-
tion, and psychological factors.
Treatment Options. There is no international consensus
on therapeutic strategy. Most patients are empirically
given antibiotics on suspicion of bacterial prostatitis, often
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accompanied by alpha blockers. Further symptom-reduc-
ing drugs and measures are applied, as well as, in certain
cases, physical therapy and psychological care [1]. In terms of
efficacy, none of these therapies offer any significant benefit
over placebo, and none of them can be recommended as
monotherapy [4].
Anatomy of the Autonomic Nervous System in the Lesser Pelvis
of the Male [5]. The innervation of ureters, urinary bladder,
seminal vesicle, and prostate occursmainly via the autonomic
nervous system. Its sympathetic and parasympathetic fibers
intermingle in the inferior hypogastric plexus. The fibers
connecting to the prostate and urinary bladder form near the
organs the closely associated plexus vesicalis and prostaticus
(“vesicoprostatic plexus”). In addition, nociceptive sympa-
thetic afferents run parallel to the axons of visceral efferents
[6].
2. Case Report
We report on a 55-year-old man who was diagnosed with
CPPS by urology specialists from the university hospital and
referred to us for pain treatmentwith local anesthetics (neural
therapy).
2.1. History and Findings. At his first consultation with us,
the patient reported pain and other ailments that began
35 years prior, after a party in a damp basement, without
vanishing ever since. In the same night, pollakisuria and
dysuria occurred, and the patient noted a permanently
painful foreign body sensation in the areas of the prostate and
anus, as well as perineally. Furthermore, he complained of a
burning sensation in the urethra, a slightly reduced urinary
stream, and nocturia of varying frequency. In addition to
the ongoing chronic pain, the patient suffered from week- to
month-long episodes of increased pain with no discernible
trigger. Overall, the pain and other symptoms progressed
over time.
Over the years, various specialist urological examinations
were carried out and several attempts at treatment with
various empirical antibiotic therapies and analgesics were
made. Also, nerve stimulation therapy was applied, and a
probatory surgical removal of both seminal vesicles and
an extension surgery on the anus were performed. None
of these measures resulted in any improvement in pain or
other symptoms. The patient was then referred to us by the
urologists for a probatory pain treatment with LA.
At the first consultation with us the patient was in a par-
ticularly severe pain phase.He complained of permanent pain
and discomfort perineally and in the areas of the prostate,
anus, and urethra, associated with pollakisuria, dysuria, and
nocturia (more than ten times per night). Due to this the
quality of life was impaired to a large degree. The patient
was desperate and did not believe that he could be helped
anymore.
For nine years he was taking an analgesically effective
antiepileptic drug, Gabapentin, as well as the nonsteroidal
anti-inflammatory drug Diclofenac, the opioid Oxycodone,
and the pain-modifying tricyclic antidepressant, Amitripty-
line.
The National Institutes of Health Chronic Prostatitis
Symptom Index (NIH-CPSI) resulted in 39 points (pain: 18;
urinary symptoms: 10; quality of life impact: 11). In rectal
palpation, the patient felt pain in the lesser pelvis while the
prostate was inconspicuous, as was the case in the recently
performed sonography, in which 50ml of residual urine had
been detected. The PSA value was found to be 0.4 ng/ml.
2.2. Treatment and Further Course. Our treatment consisted
of suprapubic injection of 5ml each of 1% procaine on the
right and the leftwith infiltration of the vesicoprostatic plexus
(in line with neural therapy). In this injection, the puncture
site is directly behind the pectineal line (pecten ossis pubis),
5 cm laterally to the center of the symphysis. The puncture
direction is 45∘ both medially and caudally. The needle point
needs always to remain extraperitoneal in the paravesical
connective tissue, in which the vegetative nerve fibers are
located. The penetration depth in the described patient was
7 cm, with the needle gauge being 23.5 (0.6mm).
Just a few minutes after the first injection, the pain
decreased significantly and persistently to a level the patient
had not experienced in years (in his own terms: 90% improve-
ment of all symptoms). In the following days, the patient
experienced a further and lasting significant reduction in
pain and other symptoms. At the next consultation after two
weeks NIH-CPSI resulted in 11 points (pain: 3; urinary symp-
toms: 4; quality of life impact: 4). To maintain and further
increase the effect, we performed the suprapubic injection of
procaine a total of six more times, initially once a month, and
bimonthly later. With each injection, the pains continued to
decrease, up to freedom from pain and discomfort. Relapses
occurred less frequently, were significantly lower in intensity
and the duration was significantly shorter with an average
of three days. Even the symptom-free intervals were getting
longer.Thepatient reducedDiclofenac andOxycodone on his
own initiative and completely discontinued both drugs after
the fifth consultation. After seven treatments, he was also able
to stop Gabapentin and Amitriptyline and remained free of
discomfort (NIH-CPSI: 0 points), which also had a positive
effect on his mental and social integrity.
2.3. Adverse Effects. No adverse effects were observed.
3. Discussion
3.1. Pathophysiological Considerations. Toour knowledge this
is the first description of a successful treatment of refractory
CPPS by infiltration of the vesicoprostatic plexus vesicopro-
staticus with a LA.
In the emergence and maintenance of chronic pain and
inflammation the sympathetic nervous system plays an
important role. Various mechanisms are involved which
sometimes amplify each other through positive feedback,
resulting in functional and structural neuronal changes. The
pathomechanisms described below are thought to be
involved in CPPS, too.
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3.1.1. Reflex Response to Nociceptive Stimuli. Visceral and
somatic nociceptive afferents converge in the spinal cord at
the same multireceptive posterior horn neurons (wide dy-
namic range neurons/WDR neurons) [7, 8]. From there,
the following circuitry is divergent: (1) via the side horn
to vegetative nuclei with activation of sympathetic efferents
innervating the visceral, cutaneous, andmuscular system; (2)
via the anterior horn to the skeletal musculature; (3) to the
brain [9–11].
Nociceptive processes trigger a reflex response that is
mediated predominantly by the sympathetic system and
occurs via cutivisceral, viscerocutaneous, viscero-somatic-
motor and reflex tracts [8, 12, 13]. In the corresponding pro-
jection zones, this can lead to pain, increased muscle tone,
and dysregulation of the associated internal organ, as well
as changes in circulation, increased skin turgor, and hyper-
algesia of certain skin areas (peripheral sensitization). This
further increases the sympathetic activity (positive feedback).
3.1.2. Sympathetic-Afferent Coupling and Sympathetic Sprout-
ing. The processes described below lead to further amplifica-
tion of the above-mentioned positive feedback. An important
factor in the development of these iterative loops is known
as “sympathetic-afferent coupling” [14–18]. In pathological
conditions, sensory coupling may occur between peripheral
sympathetic efferent nerves and afferent nociceptive neurons
by producing a kind of short circuit. Nociceptive afferents
express adrenergic receptors and can thus become susceptible
to norepinephrine [14] as a result the efferent sympathetic
system gets connected with the afferent nociceptive system:
now, enhanced sympathetic activity causes excitation of
nociceptive afferents, thus generating the perception of pain.
The process known as sympathetic sprouting, too, leads
to analogous positive feedback, in which sympathetic fibers
form basket-like structures in the dorsal root ganglia (DRG)
of the nociceptive afferents under inflammatory conditions
[19]. In terms of positive feedback (iteration), additional
minor stimuli (peripheral or central) may be sufficient in this
situation to evoke severe pain [20].
3.1.3. Synaptic Long-Term Potentiation (LTP). Neuronal ac-
tivity which is increased in the context of nociceptive pro-
cesses can lead to synaptic long-term potentiation (LTP) at the
level of the spinal cord [21] and in sympathetic ganglia [22] in
the sense of a sensitization process.The synaptic transmission
is altered, so that a consistent presynaptic stimulation can
lead to a potentiation of the postsynaptic response. Such
neuroplastic changes (“pain memory”) may cause pain to
continue to be generated even after the cause of pain has
disappeared. In fact, the patient reported that the pain
increases occurred out of the blue, i.e., without somatic or
mental triggers.
3.1.4. InhibitoryMechanisms. Gate ControlTheory deals with
the input control of the afferences in the posterior horn [23–
25]. The activity of thick A𝛽 fibers inhibits via inhibitory
interneurons the transition between the peripheral nocicep-
tive afferents and the posterior horn neurons. The collateral,
thinner A𝛿 and C fibers on the other hand counteract this
presynaptic inhibition, so that nociceptive stimuli are passed
on unhindered (“the gate opens”). Descending pathways
controlled by the cortex and brainstem normally exert presy-
naptic inhibition on the posterior horn neurons (“the gate
closes”).
The common feature of inflammatory pain states is
decreased descending inhibition [26]. Negative emotions,
too, can counteract descending inhibition and thus result in
increased transmission of nociceptive signals to the brain
[27].
3.1.5. Neuroimmunological Interaction. In addition to pain,
inflammation is part of CPPS. The sympathetic nervous sys-
tem influences immunological processes. Proinflammatory
cytokines, under certain conditions, can induce the expres-
sion of 𝛼1A adrenoreceptors on immune cells, through which
norepinephrine induces increased production of interleukin-
(IL-) 6, IL-1𝛽, tumor necrosis factor (TNF) 𝛼, and IL-8
[28, 29]. This in turn leads to an increased accumulation of
neutrophilic granulocytes and triggers a humoral immune
response [30]. In addition to norepinephrine, postganglionic
sympathetic axons also secrete neuropeptides such as sub-
stance P [9] and various prostaglandins. Nociceptive C fibers
also secrete peripherally neuropeptides such as substance P,
neurokinin A, and calcitonin gene-related peptide (CGRP)
[9, 26, 31]. These neuropeptides induce vasodilatation and
increase vascular permeabilitywith plasma extravasation [31–
33], regulate smooth muscle cell tone, and have a direct
proinflammatory effect (neurogenic inflammation) [26, 34].
In turn, IL-1𝛽 increases the synthesis of substance P [35] in
sympathetic ganglia and stimulates its secretion from afferent
nerve endings [36]. Lymphocytes and macrophages on their
part produce and secrete substance P [37, 38], leading to
further positive feedback loops of neurogenic inflammation.
3.2. Mechanisms of Action of theTherapeutic Injection of Local
Anesthetics. The well-directed injection of local anesthetics
(LA) (neural therapy) can be used to directly interfere with
the described pathomechanisms at various levels [12].
Repeated use may allow autoregulation of the pain-
processing systems due to the short-term interruption of
neuronal reflex arcs pathologically trapped in positive feed-
back [20, 39]. Clinical observations suggest that this may
also resolve structural sympathetic-afferent coupling [27]. It
has been shown that LA, including procaine, reduce sym-
pathetic sprouting in spinal ganglia with increased sponta-
neous activity [40, 41] and indirectly prevent the induction
of synaptic long-term potentiation by inhibiting extracellu-
lar signal-regulated protein kinase [42]. The repeated LA-
induced blockage of sensitized nociceptive afferent neurons
also enables themodulation of plastic changes in the neuronal
centers (“pain memory”) [10].
In the case of pain-inhibiting systems (gate control), the
goal must be to close the gate. This can be achieved with
injection treatment by means of two mechanisms: (1) the
pinprick activating the thick fibers and (2) the LA inhibiting
the thin fibers [12]. Furthermore lidocaine and procaine at
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low concentration enhance the function of glycine receptors,
of the predominant inhibitory receptors in the spinal cord,
and of GABAA receptors mediating presynaptic inhibition in
the spinal cord [43].
LA also have anti-inflammatory properties and can reg-
ulate the sympathetically mediated neurogenic inflammation
described above [12, 44]. Their effect unfolds on different
levels of the inflammatory cascade and they influence the
synthesis and release of different inflammatory mediators
[44].
Finally, LA are also antibacterial, antiviral, and antifungal
[44]. However, this comes into effect in CPPS only as an
exception, as there is usually no infection involved.
3.2.1. Advantages of Procaine. We use procaine for injection
treatments because it offers some advantages over other LA.
As a result, no long-term side effects have been reported in
over 100 years [12, 45]. Newer, long-acting LA have a less
favorable side-effect profile [45]. In addition, the effects of
injection treatment do not depend on the pharmacological
duration of action of LA. On the contrary, in order to enable
an early autoregulation of the organism, it is important to
interrupt the positive feedback in pain and inflammation
as briefly as possible [12, 45]. In addition, in contrast to
amide-structured LA, ester-structured procaine promotes
microcirculation at the site of injection not just by the
sympatholytic effect, but also by pharmacological action.
Due to the low diffusion capacity of procaine, the effect is
locally limited and therefore easily controllable [12]. 95% of
procaine is locally degraded by pseudocholinesterase, so that
the metabolism is hardly burdened [45].
4. Conclusion
Our findings and considerations suggest that in the patho-
physiology of CPPS numerous positive feedback loops (“cir-
culi vitiosi” maintained by the sympathetic nervous system)
play an important role in pain and neurogenic inflammatory
processes. Positive feedback loops can be broken by means
of injection treatments with procaine (neural therapy), which
gives the pain-processing system the opportunity to reorga-
nize. The described pathomechanisms and the mechanisms
of action of local anesthetic injection treatment show a
striking congruence, so that the latter appears to be the logical
treatment for CPPS. It has to be confirmed by clinical trials,
if the effectiveness of the presented new treatment option can
be generalized.
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